ArticleTranslational oncology2026
Single-cell analysis of TIGD genes in hepatocellular carcinoma: Prognostic value and functional characterization.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is an aggressive cancer with limited therapies. Although transposable element-derived genes are increasingly linked to tumorigenesis, the role of the TIGD family in HCC remains unclear. This study examined the expression, clinical significance, and stemness-related features of TIGDs in HCC, emphasizing their prognostic and therapeutic potential.
methodTIGD expression was analyzed using TCGA data via GEPIA2, cBioPortal, and Kaplan-Meier Plotter, with protein validation from the Human Protein Atlas. Single-cell RNA-seq data (GSE242889) were used to examine TIGD expression across hepatic cell types. Survival and Cox regression analyses assessed prognostic value, while functional enrichment and immune infiltration analyses explored biological roles. TIGD5-high and TIGD5-low epithelial subsets were compared for functional features and cell-cell communication.
resultsTIGD1, 3, 4, 5, 6, and 7 were significantly upregulated in HCC. High TIGD4, TIGD5, and TIGD6 expression correlated with poorer overall survival and served as independent prognostic markers. TIGD5 exhibited the broadest and highest expression across immune and stromal compartments. Stratification of epithelial cells into TIGD5-high and TIGD5-low subsets revealed distinct functional phenotypes: TIGD5-high cells showed enrichment in extracellular matrix organization, growth factor signaling, and immune regulatory pathways, with enhanced communication probability within the tumor microenvironment. Notably, TIGD5+ epithelial cells demonstrated increased interaction strength and MIF signaling pathway engagement compared to TIGD5- counterparts. Functional analyses indicated roles in RNA splicing, DNA replication, and cell-cycle regulation. TIGDs also showed associations with immune infiltration, particularly Th2 cells.
conclusionTIGD4, TIGD5, and TIGD6 exhibit oncogenic potential and may serve as prognostic biomarkers and therapeutic targets in HCC. Their stem-cell-associated expression highlights a novel connection between transposable element-derived genes and liver cancer stemness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.